📌 Key Takeaways
- Topic: Is Silicon Dioxide Acidic or Basic? Its Acidic Oxide Behavior Explained
- Keywords: 325 mesh silica
- Published: 2026-11-20 12:56:24
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
2500 Mesh Silica: Particle Size, Specifications and Common Applications
- Silica for Chromatography: Particle Size, Pore Size and Grade Selection
- Matting Agent for Coatings: Types, Selection Guide and Performance Comparison
- 38. Kheirkhah S., Abedi M., Zare F., Salmanpour M., Abolmaali S.S., Tamaddon A.M. Surface engineered palmitoyl-mesoporous silica nanoparticles with supported lipid bilayer coatings for high-capacity loading and prolonged release of dexamethasone: A factorial design approach. J. Drug Deliv. Sci. Technol. 2022;78:103943. doi: 10.1016/j.jddst.2022.103943. [ DOI ] [ Google Scholar ]
- What Is Hydrophobic Fumed Silica? Surface Treatment, Grades and Applications
- Fumed Silica Manufacturer: Production Process, Key Grades and How to Choose
Silicon Dioxide Side Effects: What You Need to Know
What is silica (SiO₂)?
quartz powder for ceramics
What is the difference between fumed silica and precipitated silica?
silica gel manufacturer This supports that the release rate depends on several components, among others, influenced by the pore size, the pore structure, the amount of drug loaded, the solubility of the API, and the resulting interaction between the carrier and the transported molecules [ 2 ]. By modifying these, the release kinetics can be controlled to a small extent, but a considerable influence can only be attained by surface functionalization of the mesopores. The following table contains some experimental data in terms of drug release in case of the previously shown APIs ( Table 2 ).
What drives silica raw material prices?
silica wholesale MSNs are also appropriate for pulmonary drug delivery. Inhalation is an attractive route of administration since the application is non-invasive and patient-friendly [ 18 ]. However, the rapid mucociliary clearance and the mucus hurdle complicate the intake of the API and are obstacles to be overcome [ 18, 25 ]. The mesoporous drug delivery systems may be really helpful in the treatment of lung diseases, as they can passively accumulate in the alveoli [ 25, 56, 72 ]. The passive accumulation is due to their small size, while the sizable surface area, high vascularity, and vascular permeability of the lungs enhance the process [ 56 ]. Furthermore, targeted treatment of tumors or inflamed cells can also be implemented with the functionalization of their surface [ 56, 72 ]. MSNs are typically delivered to the lungs in powder form with dry powder inhalers or suspended in liquid droplets with a nebulizer [ 56 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.